Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 2, 2021Annals of OncologyOpen Access

Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMartin ReckGerman Center for Lung ResearchDCDavid P. CarboneAstraZeneca (United Kingdom)MGMarina Chiara GarassinoUniversity of Chicago

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Reck et al. (2021) studied this question.

synapsesocial.com/papers/6a70a6756c240de38cdbe2eehttps://doi.org/10.1016/j.annonc.2021.06.001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities2015 · 948 citations
  2. 2Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer2003 · 217 citations
  3. 3The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants1997 · 1,571 citations
  4. 450 years of HPLC2016 · 70 citations